@mpgoetz

Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. Professor of Oncology and Pharmacology Tweets are my own

 Mayo Clinic
Joined April 2009
  • Tweets52
  • Following309
  • Followers365
10Media
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer. Co-authored by @GraceChoongMD, @DrJudyBoughey, and @mpgoetz #BreastCancer #bcsm Read more. brnw.ch/21wS1Ws

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer

PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER...

ascopubs.org
4
9
1,792
Replying to @rleonferre
@rleonferre @mpgoetz @MayoClinic @MayoCancerCare @MayoHemeOnc @oncodaily @OncBrothers @OncLive @IMG_Oncologists @StoriesImg #breastcancer #twincities Excellent line up of speakers; MInnesota, plz register for the presentation next week- April 10.
3
6
721
Excited to present the initial findings of the pk run-in of neoadjuvant Z-endoxifen in premenopausal women at the annual SABCS meeting
4
4
1
25
2,498
The ki-67 response rate (4 week Ki<=10%) was 86% in 22 patients. We are now ready to move this to the randomized portion comparing endoxifen with AI+ OFS
2
6
364
Congratulations to Dr. Roberto Leon Ferre for your ASCO Conquer Cancer Advanced Clinical Research Award.
1
1
11
1,498
Bottom line, ET omission in this group is associated with a 25% increased risk of death with a median follow-up of 3 years.
1
2
251
1
206
1
5
234
What is the impact of endocrine therapy omission in ER low (IHC 1-10%) breast cancer? Dr. Grace Choong presents data at ASCO 2024 regarding the detrimental impact of ET omission in this group of pts with tumors traditionally characterized as biologically similar to TNBC
1
2
1
8
1,327
📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current jamanetwork.com/journals/jam…
5
37
10
99
34,391
IT’S GREAT TO BE A MICHIGAN WOLVERINE! #GoBlue
2023 National Champions

ALT 2023 National Champions

1,054
13,003
1,589
33,658
2,433,727
Endoxifen is known to be a more potent inhibitor of ER alpha compared to tamoxifen.  Based on an unbiased proteomic screen, we identify protein kinase beta as a new endoxifen drug target, resulting in suppression of AKT signaling and apoptosis pubmed.ncbi.nlm.nih.gov/3811…

Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+...

Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical...

pubmed.ncbi.nlm.nih.gov
2
1
3
425
In premenopausal women with ER+/HER2- breast cancer, the neoadjuvant EVANGELINE trial is testing the hypothesis that dual targeting of ER and PKC beta will result in substantial anti tumor activity without the need for ovarian function suppression evangelinetrial.com/
4
255
Jack Cuzick shows the benefit of anastrozole in IBIS -II according to baseline estradiol levels at the SABCS McGuire lecture. Potentially practice changing.
3
256
Matthew Goetz retweeted
Judy Boughey@DrJudyBoughey3 Nov 2023
Replying to @ALLIANCE_org
@ALLIANCE_org plenary session. New group chair Dr Eva Galanis @MayoCancerCare opens the plenary session.
1
3
269
It was a pleasure to present these data. Critically important, as any biomarker needs to be fully validated before being used to select patients. In this case, these biomarkers are prognostic but clearly not predictive of abemacicib benefit.
Stephanie Graff, MD, FACP, FASCO@DrSGraff23 Oct 2023
Consistent invasive disease free survival benefit of adjuvant abemaciclib in #MonarchE regardless of ER, PR or Ki-67 expression. #ESMO23 @OncoAlert
1
1
6
1,361
Congratulations to Dr. Sid Yadav and Fergus Couch on their ASCO presentation demonstrating that P/LP missense variants carry same lifetime breast cancer risk as DBD truncating variants
3
30
1,708
Register now to attend @OncLive's Institutional Perspectives in Cancer virtual event for #BreastCancer, led by @MayoClinic experts @mpgoetz and @DrJudyBoughey. See the overview, featured topics and register here: mayocl.in/3Ca6IMv
4
11
1,958
Women with #BreastCancer in one breast may be at higher risk of developing cancer in the opposite breast if they have a #BRCA1, #BRCA2 or CHEK2 mutation, according to a study led by @MayoClinic Comprehensive Cancer Center. Read more: mayocl.in/3XGBuVN
2
5
648
Dr. Matthew Goetz discusses his #ELAINE2 #BreastCancer research poster presented at @SABCSSanAntonio.
3
9
Load more